Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Thompson Investment Management Inc.

Thompson Investment Management Inc. lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,830 shares of the company’s stock after selling 920 shares during the quarter. Thompson Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $1,205,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Cetera Investment Advisers boosted its stake in shares of Neurocrine Biosciences by 7.9% in the second quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after buying an additional 519 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter worth about $510,000. GAMMA Investing LLC boosted its stake in shares of Neurocrine Biosciences by 11.9% in the third quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after buying an additional 185 shares during the last quarter. CWM LLC boosted its stake in shares of Neurocrine Biosciences by 15.1% in the third quarter. CWM LLC now owns 7,884 shares of the company’s stock worth $908,000 after buying an additional 1,035 shares during the last quarter. Finally, Perpetual Ltd boosted its stake in shares of Neurocrine Biosciences by 96.6% in the third quarter. Perpetual Ltd now owns 12,560 shares of the company’s stock worth $1,447,000 after buying an additional 6,170 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matt Abernethy sold 1,283 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $196,132.21. Following the completion of the sale, the chief financial officer now owns 32,681 shares in the company, valued at approximately $4,995,944.47. This represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 222,693 shares of company stock worth $32,718,279 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Down 18.5 %

NASDAQ:NBIX opened at $122.62 on Friday. The firm has a market cap of $12.42 billion, a PE ratio of 37.27 and a beta of 0.33. The stock has a fifty day moving average price of $138.81 and a 200 day moving average price of $131.62. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on NBIX shares. Royal Bank of Canada lowered their target price on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research note on Friday. Piper Sandler reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday. Finally, Canaccord Genuity Group reduced their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a report on Friday. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $169.20.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.